Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover st...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jin Ah, Lee, Soo-Yun, Kim, Tae-Eun, Kim, Jung-Ryul, Kim, Chin, Huh, Wooseong, Ko, Jae-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/
https://www.ncbi.nlm.nih.gov/pubmed/25767371
http://dx.doi.org/10.2147/DDDT.S76591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/
https://www.ncbi.nlm.nih.gov/pubmed/25767371
http://dx.doi.org/10.2147/DDDT.S76591

Ejemplares similares